title: Functional and biochemical analysis of angiotensin II-forming pathways in the human heart.
abstract: Blockade of the renin-angiotensin system by inhibition of angiotensin-converting enzyme (ACE) is beneficial for the treatment of hypertension and congestive heart failure. However, it is unclear how complete the blockade by ACE inhibitors is and if there is continuing angiotensin II (Ang II) formation during chronic treatment with ACE inhibitors. Indeed chymase, a serine protease, which is able to form angiotensin II from angiotensin I (Ang I) and cannot be blocked by ACE inhibitors, has been shown to be present in human heart. The goal of the present study was to evaluate the extent of renin-angiotensin system blockade and the Ang II-forming pathways in cardiac tissue of patients chronically treated with ACE inhibitors or in patients without ACE inhibition therapy. Our studies indicate an incomplete ACE inhibition in human heart tissue after chronic ACE inhibitor therapy. Moreover, ACE contributes only a small portion to the total Ang I conversion, as shown in biochemical studies in ventricular and coronary homogenates or functionally as Ang I contractions in isolated rings of coronary arteries. A serine protease was responsible for the majority of Ang II production in both the membrane preparation and Ang I-induced contractions of isolated coronary arteries. In humans, the serine protease pathway is likely to play an important role in cardiac Ang II formation. Thus, drugs such as renin inhibitors and Ang II receptor blockers might be able to induce a more complete blockade of the renin-angiotensin system, providing a more efficacious therapy.
authors.affiliation: Pharma Division, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
authors.forename: A
authors.initials: A
authors.lastname: Wolny
authors.forename: J P
authors.initials: JP
authors.lastname: Clozel
authors.forename: J
authors.initials: J
authors.lastname: Rein
authors.forename: P
authors.initials: P
authors.lastname: Mory
authors.forename: P
authors.initials: P
authors.lastname: Vogt
authors.forename: M
authors.initials: M
authors.lastname: Turino
authors.forename: W
authors.initials: W
authors.lastname: Kiowski
authors.forename: W
authors.initials: W
authors.lastname: Fischli
mesh_terms: D000328:Adult; D000804:Angiotensin II / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D053818:Chymases; D006801:Humans; D008297:Male; D008875:Middle Aged; D009206:Myocardium / Q000378:metabolism*; D012084:Renin-Angiotensin System; D012697:Serine Endopeptidases / Q000378:metabolism
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000804:Angiotensin II; D012697:Serine Endopeptidases; D053818:Chymases